MX2016001030A - Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. - Google Patents

Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.

Info

Publication number
MX2016001030A
MX2016001030A MX2016001030A MX2016001030A MX2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A
Authority
MX
Mexico
Prior art keywords
compositions
methods
desmopressin
beta
combination
Prior art date
Application number
MX2016001030A
Other languages
English (en)
Spanish (es)
Inventor
H Fein Seymour
Herschkowitz Samuel
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2016001030A publication Critical patent/MX2016001030A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/095Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
MX2016001030A 2013-07-23 2014-07-23 Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. MX2016001030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857431P 2013-07-23 2013-07-23
PCT/US2014/047899 WO2015013454A1 (en) 2013-07-23 2014-07-23 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist

Publications (1)

Publication Number Publication Date
MX2016001030A true MX2016001030A (es) 2016-10-07

Family

ID=51299056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001030A MX2016001030A (es) 2013-07-23 2014-07-23 Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.

Country Status (11)

Country Link
US (2) US9814753B2 (OSRAM)
EP (1) EP3024474B1 (OSRAM)
JP (2) JP2016525548A (OSRAM)
KR (3) KR20240015735A (OSRAM)
CN (1) CN105579057A (OSRAM)
AU (1) AU2014293141A1 (OSRAM)
CA (1) CA2919198A1 (OSRAM)
DK (1) DK3024474T3 (OSRAM)
ES (1) ES2910361T3 (OSRAM)
MX (1) MX2016001030A (OSRAM)
WO (1) WO2015013454A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
MX343193B (es) 2009-06-18 2016-10-26 Allergan Inc Administracion segura de desmopresina.
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
MX2016001032A (es) 2013-07-23 2017-10-31 Allergan Inc Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.
DK3024474T3 (da) 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
EP3220942B1 (en) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist
EA201791225A1 (ru) 2014-12-03 2017-12-29 Велисепт Терапьютикс, Инк. Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
WO2017210700A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
IL101243A (en) 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
WO1999027905A1 (en) 1997-12-02 1999-06-10 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Compositions for nasal administration
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US6939324B2 (en) 2000-11-30 2005-09-06 Biovalve Technologies, Inc. Fluid delivery and measurement systems and methods
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
USRE44872E1 (en) * 2002-11-07 2014-04-29 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
EP2322198A2 (en) 2003-11-10 2011-05-18 Reprise Biopharmaceutics, LLC Pharmaceutical compositions including low dosages of desmopressin
DE602004028284D1 (de) 2003-12-08 2010-09-02 Cpex Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
WO2007072156A1 (en) 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
JPWO2007083640A1 (ja) * 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
US8399410B2 (en) 2007-08-06 2013-03-19 Allergan, Inc. Methods and devices for desmopressin drug delivery
CN101648017A (zh) 2008-08-12 2010-02-17 许洁 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物
EP2361092A4 (en) 2008-09-04 2012-07-11 Anthony I Rozmanith HEALTH CARE
CA2747998C (en) 2008-12-22 2016-05-31 Allergan, Inc. Safe desmopressin administration
US20100160214A1 (en) 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
MX343193B (es) 2009-06-18 2016-10-26 Allergan Inc Administracion segura de desmopresina.
EP2485595A4 (en) * 2009-10-07 2014-03-12 Merck Sharp & Dohme COMBINATION THERAPY WITH AN ADRENERGIC BETA-3 RECEPTOR AGONIST AND ANTIMIC CARCINU
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
JP2014510045A (ja) 2011-02-08 2014-04-24 ハロザイム インコーポレイテッド ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
BR112014020271A8 (pt) 2012-03-19 2017-07-11 Wellesley Pharmaceuticals Llc Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
DK3024474T3 (da) * 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
MX2016001032A (es) 2013-07-23 2017-10-31 Allergan Inc Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.
CA2923270A1 (en) 2013-09-03 2015-03-12 Shin Nippon Biomedical Laboratories Ltd. (Snbl) Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
EP3220942B1 (en) 2014-11-20 2022-04-27 Serenity Pharmaceuticals LLC Compositions comprising low dose desmopressin in combination with an alpha-adrenergic receptor antagonist

Also Published As

Publication number Publication date
DK3024474T3 (da) 2022-03-28
AU2014293141A1 (en) 2016-02-18
KR20240015735A (ko) 2024-02-05
KR20160033220A (ko) 2016-03-25
EP3024474A1 (en) 2016-06-01
US20150031613A1 (en) 2015-01-29
CN105579057A (zh) 2016-05-11
US10568927B2 (en) 2020-02-25
ES2910361T3 (es) 2022-05-12
JP2020109122A (ja) 2020-07-16
US9814753B2 (en) 2017-11-14
JP7219736B2 (ja) 2023-02-08
CA2919198A1 (en) 2015-01-29
KR20210103589A (ko) 2021-08-23
US20180289769A1 (en) 2018-10-11
WO2015013454A1 (en) 2015-01-29
JP2016525548A (ja) 2016-08-25
EP3024474B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
MX2016001030A (es) Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
SG11201705917PA (en) Low density polishing pad
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
IL240393B (en) Il-33 antagonists and their uses
GB201521064D0 (en) Test bench combining high-frequency tribological stress and oligocyclic fatigue
EP2947168A4 (en) THERMALLY CALIBRATED STEEL MACHINE WIRE HAVING EXCELLENT FATIGUE PROPERTIES, AND SPRING USING THE SAME
ZA201506131B (en) Kv1.3 antagonists and methods of use
SG11201505900XA (en) Polishing pad
IL256208A (en) Biomarkers associated with lsd1 inhibitors and their uses
PT3221514T (pt) Palmilha de travessa
SG10201403725TA (en) Polishing apparatus, polishing pad positioning method, and polishing pad
PL2997345T3 (pl) Stanowisko badawcze do badań zmęczeniowych przy obciążeniu niskocyklowym i wysokocyklowym
PL4215137T3 (pl) Narzędzie kriochirurgiczne
PL3013855T3 (pl) Zmutowany czynnik viii – kompozycje i sposoby wytwarzania
SG11201505907PA (en) Compositions and methods for pain relief without numbness
PL3215676T3 (pl) Punkt mocujący szyny i płyty podkładowej
SG11201505923QA (en) Polishing pad
IN2014CN00312A (OSRAM)
IL276431A (en) Treatment of the brain disorders and related symptoms
PL3019242T3 (pl) Kompozycje i sposoby leczenia zaburzeń neuropsychiatrycznych przy zastosowaniu agonisty receptora endoteliny-B
PL3452659T3 (pl) Warstwa pośrednia szyny
TWI563074B (en) Nickel phosphorous cmp compositions and methods
MX2017006655A (es) Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico.
MX2016001032A (es) Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.